ACE2 and COVID-19: The presence of GI symptoms, widely described in COVID-19 case series and present in 3–11.6% of patients with COVID-19 [31], has been associated with high ACE2 expression in the GI tract that could indicate the potential of virus mutation towards increased transmissibility, decreased virulence, and multiorgan infection [31].